08049 JILIN CHANGLONG
- 1.580
- -0.010-0.63%
JILIN CHANGLONG News
JILIN CHANGLONG To Go Ex-Dividend On June 18th, 2024 With 0.06888 HKD Special Dividend Per Share
April 26th - $JILIN CHANGLONG(08049.HK)$ is trading ex-dividend on June 18th, 2024. Shareholders of record on June 19th, 2024 will receive 0.06888 HKD special dividend per share on July 16th, 2024
Jilin Changlong Pharmaceutical (08049) will pay a special dividend of 0.0625 yuan per share on July 16
Jilin Changlong Pharmaceutical (08049) announced that the company will pay a special dividend per share on July 16, 2024...
吉林長龍藥業：宣派及派付特別股息及 暫停辦理股份過戶登記手續
吉林長龍藥業：董事會會議通告及建議宣派及派付特別股息
Jilin Changlong Pharmaceutical (08049) announced annual results. Profit attributable to shareholders of 148 million yuan decreased by 23.43% year-on-year
Jilin Changlong Pharmaceutical (08049) announced results for the year ended December 31, 2023, and the group obtained revenue...
JILIN CHANGLONG: ANNUAL REPORT 2023
JILIN CHANGLONG: 2023 ANNUAL RESULTS ANNOUNCEMENT
Jilin Changlong Pharmaceutical (08049.HK): subscribed to 100 million yuan structured deposit products from ICBC
Gelonghui March 12, 丨 Jilin Changlong Pharmaceutical (08049.HK) issued an announcement. On March 12, 2024, the company subscribed to structured deposit products from the Industrial and Commercial Bank of China for an amount of RMB 10 million.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Improved Earnings Required Before Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049) Stock's 25% Jump Looks Justified
The Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049) share price has done very well over the last month, posting an excellent gain of 25%. The last 30 days bring the annual g
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Jilin Changlong Pharmaceutical announced the first three quarter results, profit attributable to shareholders of 133 million yuan, up 27.36% year-on-year
Jilin Changlong Pharmaceutical (08049) announced results for the first three quarters of the nine months ended September 30, 2023, with a turnover of 593 million yuan (RMB, same below), a year-on-year decrease of 0.1%; profit attributable to equity holders of 133 million yuan, an increase of 27.36% over the previous year; and profit per share of 23.79 points.
Analysis
Price Target
No Data
